Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma

Overview

Journal Hematol Oncol Clin North Am

Specialties Hematology
Oncology

Date 2023 Dec 29

PMID 38158242

Authors

Zainul S Hasanali

Beatrice Razzo

Sandra P Susanibar-Adaniya

Alfred L Garfall

Edward A Stadtmauer

Adam D Cohen

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor T cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) drug approvals and opened the door to the development of this drug class. This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions.

References

Ramos C, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O . Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016; 126(7):2588-96. PMC: 4922690. DOI: 10.1172/JCI86000. View

Matsui W, Wang Q, Barber J, Brennan S, Smith B, Borrello I . Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008; 68(1):190-7. PMC: 2603142. DOI: 10.1158/0008-5472.CAN-07-3096. View

Frey N, Porter D . Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant. 2018; 25(4):e123-e127. DOI: 10.1016/j.bbmt.2018.12.756. View

Mailankody S, Devlin S, Landa J, Nath K, Diamonte C, Carstens E . GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022; 387(13):1196-1206. PMC: 10309537. DOI: 10.1056/NEJMoa2209900. View

Jiang D, Huang H, Qin H, Tang K, Shi X, Zhu T . Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat Commun. 2023; 14(1):3642. PMC: 10282100. DOI: 10.1038/s41467-023-39395-4. View

Zhao W, Liu J, Wang B, Chen Y, Cao X, Yang Y . A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018; 11(1):141. PMC: 6302465. DOI: 10.1186/s13045-018-0681-6. View

Petersen C, Hassan M, Morris A, Jeffery J, Lee K, Jagirdar N . Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists. Blood Adv. 2018; 2(3):210-223. PMC: 5812323. DOI: 10.1182/bloodadvances.2017011254. View

Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L . Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res. 2017; 24(1):106-119. PMC: 5991104. DOI: 10.1158/1078-0432.CCR-17-0344. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

10.

Rodriguez-Otero P, Ayers D, Cope S, Davies F, Delforge M, Mojebi A . Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2021; 62(10):2482-2491. DOI: 10.1080/10428194.2021.1913143. View

11.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

12.

Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M . Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023; 29(9):2295-2306. PMC: 10504087. DOI: 10.1038/s41591-023-02491-5. View

13.

Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y . Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial. J Clin Oncol. 2023; 41(14):2583-2593. PMC: 10414745. DOI: 10.1200/JCO.22.01824. View

14.

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

15.

Radhakrishnan S, Luetkens T, Scherer S, Davis P, Vander Mause E, Olson M . CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun. 2020; 11(1):798. PMC: 7005855. DOI: 10.1038/s41467-020-14619-z. View

16.

Wong D, Roy N, Zhang K, Anukanth A, Asthana A, Shirkey-Son N . A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. 2022; 13(1):217. PMC: 8752722. DOI: 10.1038/s41467-021-27853-w. View

17.

Hansen D, Sidana S, Peres L, Colin Leitzinger C, Shune L, Shrewsbury A . Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023; 41(11):2087-2097. PMC: 10082273. DOI: 10.1200/JCO.22.01365. View

18.

Cohen A, Mateos M, Cohen Y, Rodriguez-Otero P, Paiva B, van de Donk N . Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2022; 141(3):219-230. PMC: 10562529. DOI: 10.1182/blood.2022015526. View

19.

Li C, Xu J, Luo W, Liao D, Xie W, Wei Q . Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2023; 38(1):149-159. PMC: 10776387. DOI: 10.1038/s41375-023-02065-x. View

20.

Milone M, Fish J, Carpenito C, Carroll R, Binder G, Teachey D . Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17(8):1453-64. PMC: 2805264. DOI: 10.1038/mt.2009.83. View